ロード中...
Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
BACKGROUND: T cell-based immunotherapies using chimeric antigen receptors (CAR) or bispecific antibodies (BsAb) have produced impressive responses in hematological malignancies. However, major hurdles remained, including cytokine release syndrome, neurotoxicity, on-target off-tumor effects, reliance...
保存先:
| 出版年: | J Immunother Cancer |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8126293/ https://ncbi.nlm.nih.gov/pubmed/33986124 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002222 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|